Chapter 2

Cash Conversion

Vital Farms grew net revenue from roughly $107M to $759M over eight fiscal years and earned $166M of cumulative net income — yet turned only about $10M of that into cumulative free cash flow, roughly six cents on the dollar. The rest went to capital spending and, in 2025, a large working-capital build. Free cash flow has been thin, lumpy, and is now in its deepest trough as the company funds its largest-ever capacity build into a commodity-egg price shock. The balance sheet can fund it; the durability of the cash generation on the other side is the open question.

The record: profit has rarely become free cash

Source: derived from reported financials; FY2025 Annual Report (Form 10-K), Consolidated Statements of Cash Flows [1].

The single most useful lens on this business is how reliably reported earnings convert to cash a shareholder could take out. Over eight years, they largely have not. Cumulative operating cash flow of $177M funded cumulative capex of $166M, leaving about $10M of cumulative free cash flow against $166M of cumulative net income [2]. Free cash flow was negative in three of the eight years and never exceeded $40M in any of them.

Source: derived from reported financials, FY2018–FY2025 10-Ks; FY2023–FY2025 figures per FY2025 Annual Report, Consolidated Statements of Cash Flows [3].

Two things are true at once here. The reinvestment has worked: the capital that suppressed free cash flow also grew the business more than sevenfold and lifted operating margin from near zero to double digits. And even in the two best years — FY2023 and FY2024 — free cash flow of $39M and $36M represented free-cash-flow margins of only 8% and 6%. This is not yet a high-cash-conversion business; it is a fast-growing one that has plowed nearly all its operating cash back into capacity.

FY2025: why record profit produced negative cash

The FY2025 swing was large and has two distinct causes. Free cash flow fell $84M year-on-year, from positive $36M to negative $48M. Roughly two-thirds of that is deliberate growth capital; the remainder is a working-capital build that deserves closer attention.

Source: derived from FY2025 Annual Report, Consolidated Statements of Cash Flows [4].

Capex tripled to $82.0M as the company broke ground on Vital Crossroads — a second automated egg washing and packing plant in Seymour, Indiana — and built a second processing line at Egg Central Station simultaneously rather than in phases [5]. Against depreciation of $13.8M and a pre-build capex run-rate near $11M–$15M, roughly $67M of the $82M is genuine growth investment, not maintenance [6]. That portion is discretionary and, as 2026 has since shown, reversible.

The second cause is less discretionary. Operating cash flow itself fell from $64.8M to $33.7M even as net income rose, because inventory swung from an $8.9M source of cash in 2024 to a $47.8M use in 2025, and lease payments consumed a further $34.7M [7]. Inventory on the balance sheet nearly tripled, from $23.7M to $66.5M [8].

Source: FY2025 Annual Report (Form 10-K), Note 8 — Inventories [9].

The egg inventory line quadrupled, and the reserve for inventory obsolescence jumped from $0.2M to $4.9M in a single year [10]. Building inventory while writing more of it down was an early signal of a structural feature that became the central story of 2026: because Vital Farms contracts to buy eggs from its farmer network regardless of retail demand, a demand slowdown does not reduce supply — it becomes surplus eggs the company must move at a loss.

The 2026 reset: the commodity link, made visible

Through 2025, management framed negative free cash flow as a choice. On the second-quarter 2025 call, the CFO said the company expected "free cash flow to turn negative this year after two very strong positive years," having pulled Seymour capex forward, and reiterated that every capex dollar in Seymour should generate more than $5 of annual revenue capacity [11]. In February 2026, the company guided FY2026 capex up again to $140M–$150M and told investors to expect "a meaningful pivot to strong, sustainable free cash flow generation in 2027 and beyond, once the heavy spending" was complete, alongside a reaffirmed target of $2 billion of net revenue by 2030 and a new $100M buyback authorization [12].

Ten weeks later, that plan changed materially. On the May 2026 first-quarter call, management reported a first-quarter net loss of $1.5M against a $16.9M profit a year earlier, with adjusted EBITDA margin collapsing from 17% to under 3% [13]. The cause was a commodity-price collapse: as mainstream egg prices fell to multi-year lows — breaker eggs traded as low as $0.10 per dozen — Vital Farms' price gap to competitors widened past what its brand could hold, new-household trial dropped, and the company found itself with surplus eggs it had contracted to buy [14]. Management said it had "found the limits of what our brand could sustain" [15].

The cash response was a sharp reversal of the prior six months of guidance.

Source: Q4 FY2025 Earnings Call [16]; Q1 FY2026 Earnings Call [17].

Between February and May, the FY2026 revenue guide fell from $900M–$920M to $775M–$800M, the adjusted EBITDA guide fell from $105M–$115M to $0–$10M, and the capex guide was cut from $140M–$150M to $70M–$75M [18]. To preserve cash, management decided to exit the butter business entirely (freeing an estimated $25M and cutting about $14M of 2026 revenue), eliminated roughly 10% of non-plant headcount, and slowed Seymour construction while pausing accelerator-farm build-out [19]. The company still expects "negative free cash flow this year" and now anticipates funding it partly through its revolver [20].

Can it fund the trough

For a value investor the first cash question is solvency, and here the answer is reassuring, if less comfortable than a year ago. Vital Farms carries no term debt. It holds a $60.0M five-year revolving facility with JPMorgan, undrawn at year-end 2025, with financial covenants of a net leverage ratio no greater than 3.25x and a fixed-charge coverage ratio no less than 1.35x [21].

The cushion is shrinking quickly, though. Cash, equivalents and marketable securities fell from $113.4M at year-end 2025 to $51.4M by the end of the first quarter of 2026 — a $62M draw in one quarter, reflecting the inventory build, supply-management costs, continued capex, and $20M of buybacks [22]. With capex now cut to $70M–$75M, the butter exit adding cash, and $60M of undrawn revolver capacity, the near-term funding gap looks manageable, and there is no near-term maturity to refinance. The binding constraint to watch is not liquidity itself but the fixed-charge coverage covenant if adjusted EBITDA sits near the bottom of the $0–$10M guide and the company draws the revolver — a threshold worth checking each quarter. Solvency is not the risk today; the risk is that a further leg down in category pricing, which management explicitly flagged as possible, deepens and lengthens the cash draw.

One capital-allocation choice sits awkwardly against that draw: the board authorized a $100M, two-year buyback in February and had spent $20M of it by March, with $80M remaining, while free cash flow was negative and cash was falling [23]. Repurchasing a stock down heavily from its peak can be accretive if the recovery arrives; funding it from a shrinking cash pile during the company's deepest cash trough is a bet that the trough is temporary. On the accounting side, the one governance-adjacent flag on cash and earnings quality — a material weakness in revenue and accounts-receivable controls identified for FY2024 — was remediated as of December 28, 2025, with no restatement [24].

The pivot the case depends on

The setup is the kind a patient investor is built for: a category leader in its deepest cash trough, spending heavily now against a promise of harvest later. Management's math is internally coherent. If Seymour delivers more than $5 of revenue capacity per capex dollar, if the $2 billion 2030 revenue target is met at a 15%–17% adjusted-EBITDA margin, and if capex normalizes toward maintenance once the plants are built, steady-state free cash flow could plausibly reach $150M–$180M a year — a genuine owner-cash business [25]. The category tailwind is real: outdoor-access eggs grew from 8% of category volume in 2023 to 15% by early 2026, even with commodity eggs at their cheapest in years [26].

The case against giving that promise the benefit of the doubt rests on three facts, and they deserve equal weight. First, the guidance has moved a long way, fast: the FY2026 adjusted-EBITDA outlook fell from roughly $110M to about $5M in ten weeks, which is a wide miss on management's own near-term forecasting. Second, the surplus-egg episode is not a one-off macro event but a visible expression of the model itself — fixed egg supply meeting variable demand — which caps how much of a commodity-cost swing the brand premium can absorb. Third, "strong, sustainable free cash flow" has been asserted, not demonstrated: across eight public years the company has generated about $10M of it in total, and the promised 2027 pivot has already slipped once as capex was cut to defend the balance sheet rather than to build the capacity the growth target requires.

My read is that Vital Farms is a credible franchise that has not yet proven it can convert profit into durable owner cash, and that 2026 is the year the model's commodity exposure and its cash-conversion question are being tested in the open rather than in theory. The evidence for the bull case is the category's growth and the clean, debt-free balance sheet; the evidence against is a low structural free-cash-flow margin, rising working-capital intensity, and a forecasting record that has just been marked down hard. What would change the read in either direction is concrete and checkable: adjusted EBITDA re-crossing double-digit margins and inventory normalizing back toward one turn of its 2024 level would support the harvest thesis; a second downward capex-or-EBITDA revision, or a revolver draw that puts the fixed-charge covenant in play, would confirm the skeptic's.